CG Oncology (CGON) Interest & Investment Income (2023 - 2026)

CG Oncology has reported Interest & Investment Income for 4 years, with the latest figure at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 18.83% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $28.5 million (down 1.23% YoY), and the FY2025 full-year result was $29.9 million, up 12.42% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $6.3 million, down from $7.4 million in the prior quarter.
• The five-year high for Interest & Investment Income was $7.9 million in Q3 2024, with the low at $771000.0 in Q2 2023.
• Historically, Interest & Investment Income has averaged $5.4 million across 4 years, with a median of $6.3 million in 2026.
• Annual changes were most pronounced in 2024 — Interest & Investment Income jumped 800.52% — and 2026, when it decreased 18.83%.
• CG Oncology's Interest & Investment Income stood at $2.8 million in 2023, then jumped by 122.72% to $6.2 million in 2024, then climbed by 19.2% to $7.4 million in 2025, then declined by 15.53% to $6.3 million in 2026.
• The last three Interest & Investment Income figures came in at $6.3 million (Q1 2026), $7.4 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.